| | |
| Formerly |
|
|---|---|
| Company type | Public |
| ASX: AVR | |
| Industry | Biotechnology |
| Headquarters | , Australia |
| Website | anteristech |
Anteris Technologies Limited is an Australian biotechnology company.
Anteris originates from the merger of Allied Medical and BioMD. Allied Medical was a company spun out of mining company Fortescue in 2005 which focused on selling medical equipment such as catheters. [1] It entered the biotechnology space in July 2010 when it purchased a 38.6 per cent stake in Brisbane-based Coridon for A$3 million. [2] By February 2011, its stake increased to 55 per cent. [3] In February 2011, Allied Medical agreed to a reverse takeover deal with BioMD, a listed biotech company. [3] The takeover was completed in June 2011 resulting in the combined company, Allied Healthcare Group, listing on the Australian Securities Exchange (ASX). [4] [5] [6]
In September 2012, Allied raised $10.4 million to launch CardioCel across Europe. [7] In November 2013, Allied Healthcare changed its name to Admedus. [8] In December 2013, Admedus purchased a manufacturing site in Malaga to scale-up production of CardioCel and support the development and manufacture of additional regenerative tissue products. [7]
In October 2019, Admedus sold its CardioCel and VascuCel patch business to U.S.-based LeMaitre Vascular. [9] Under the agreement, Admedus received A$22.8 million upfront followed by deferred payments of $1 million each at 12 months and at 36 months. Additionally, the company could receive up to $11.4 million in earn-out payments. [10] Admedus retained the right to manufacture CardioCel and VascuCel products at its Malaga facility for LeMaitre over the following three years. [9] In May 2020, Admedus changed its name to Anteris Technologies. [11]